Wednesday, July 8, 2026

pharma · Amyotrophic Lateral Sclerosis · Pharmacokinetics · NRSN

NeuroSense Therapeutics

NeuroSense Therapeutics trial registry — 6 ClinicalTrials.gov studies with program phase, status, and indication context.

Cambridge, USA HQ
2017 Founded
30 Employees
Public company Type
NRSN · NYSE Ticker
Company details
Status
Public
HQ
Cambridge, USA
Founded
2017
Employees
30
Programs
6
Drugs
6
Patents
2
Intelligence · Clinical Trials

NeuroSense Therapeutics clinical trials

Registry index of 6 ClinicalTrials.gov studies linked to NeuroSense Therapeutics programs — each row shows trial ID, program name, phase, status, and indication.

NeuroSense Therapeutics trial registry — 6 ClinicalTrials.gov studies with program phase, status, and indication context.

Recent trial activity

6 updates

Latest clinical program signals indexed for NeuroSense Therapeutics.

  1. Fixed dose combination Ciprofloxacin/Celecoxib — Phase 2

    Clinical update
  2. Fixed dose combination Ciprofloxacin/Celecoxib — Phase 1

    Clinical update
  3. PrimeC — Phase 2

    Clinical update
  4. PrimeC — Phase 2

    Clinical update
  5. PrimeC 748 mg — Phase 1

    Clinical update
  6. PrimeC-ER 748 mg — Phase 1

    Clinical update

Trial registry

6 studies